"An ecosystem is the only way forward to accelerate CGT development for more patients," Pang told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. "We're building out our full digital platform across the entire value chain, from the patient all the way through clinic through manufacturing and then back for patient delivery and beyond."
Pang sees Autolomous' digital platform as the "glue" that holds together disparate systems and equipment from different suppliers. Looking ahead, the COO said that connecting to clinical data will be important to better understand the "variability in the patient material" to make it more likely to identify "which products are successful long term" as well as support reimbursement models.
In October, Autolomous formed a strategic partnership with Vineti to deliver end-to-end supply chain management solutions for the CGT sector. Pang said the collaboration will better integrate the clinic with manufacturing.
Watch the video below to learn more.